Hasan Jafri

Dr. Hasan Jafri leads clinical development of the anti-bacterial monoclonal antibodies within the Serious Bacterial Infections Franchise at MedImmune, AstraZeneca. He has previously been involved in the design and conduct of multiple Phase 1‐4 clinical studies to assess novel small and large molecules against bacterial, viral and fungal pathogens. Prior to joining MedImmune, Dr. Jafri served as a professor in the department of pediatric infectious diseases and the department of clinical science research at the University of Texas Southwestern Medical Center at Dallas. He was the Chief of Division of Clinical Pharmacology, director of the Pediatric Infectious Diseases fellowship program, and director of the NICHD Pediatric Pharmacology Research Center. He has also served at the US Center for Disease Control and Prevention (CDC). He has over 25 years of experience in clinical practice and research, especially in the area of serious healthcare associated and community acquired infections, respiratory viral infections and invasive fungal infections (in immunocompromised and immunocompetent hosts), and biomarker and translational research. Dr. Jafri serves as the industry lead on the Innovative Medicines Initiative (IMI) COMBACTE programs involving development of MedImmune, AstraZeneca’s novel antibacterial monoclonal antibodies, and serves as the overall Coordinator of the COMBACTE-NET and COMBACTE-MAGNET Public-Private consortia. He also serves as the AstraZeneca representative, and leads the clinical subteam within the Infectious Disease Strategic Governance Group (SGG), an industry committee tasked with advising the European Commission and IMI on EFPIA R&D priorities. He has authored over 70 peer reviewed journal articles and presented over 100 original research abstracts at National and International Conferences.